October 18-20 | Tucson, AZ

The Research Institution GAP Fund and Accelerator Program Summit

TEDCO’s Pre-Seed Builder Fund Invests in Maryland Medical Device Start-up · BioBuzz

Get our GAP Insights Newsletter

Join Us

October 23-25, 2024 / Atlanta, GA

The annual summit for research institution gap fund and accelerator programs, including proof of concept programs, startup accelerators, and university venture funds

The Story

COLUMBIA, Md. (March 18, 2022)TEDCO, Maryland’s economic engine for technology companies, announced today its Builder Fund invested $100,000 in Astek Diagnostics, a medical device start-up based in Maryland. TEDCO’s Builder Fund invests in and provides executive support to Maryland-based technology companies run by entrepreneurs who demonstrate economic disadvantage.

Astek Diagnostics

“We know that getting the correct anti-biotics to patients suffering from sepsis is absolutely crucial to their wellbeing; that’s why Astek Diagnostics has developed our life-saving Eugris platform,” said Mustafa Al-Adhami, CEO of Astek Diagnostics. “We couldn’t do it alone; our team brought the innovative thinking, while TEDCO offered collaboration and timely investments. We’re very grateful to TEDCO, and we look forward to a productive partnership as we work to bring our  platform to market.”

Astek Diagnostics, Inc., based in Baltimore, is a University of Maryland, Baltimore County spinout that is building a platform (Eugris) that guides physicians in prescribing appropriate antibiotics for patients with bacterial sepsis in one hour. Sepsis is a life-threatening condition that affects more than one million patients a year in the United States, and even more patients around the globe. Sepsis is the cause of more than 8 million deaths worldwide. For patients suspected of sepsis or septic shock, rapid initiation of the correct antibiotic therapy is crucial: Every hour of delay increases mortality by 7-8 percent. A proof-of-concept prototype of the Astek diagnostic platform has been verified using commercial blood and archived clinical samples. The Eugris is projected to launch in the market 2023.

“With its exciting new platform, Astek Diagnostics has the potential to save thousands or even millions of lives from sepsis-related deaths,” said Jean-Luc Park, senior director of Social Impact Funds at TEDCO. “Maryland entrepreneurs who are working on ground-breaking science and tech solutions should reach out to TEDCO to connect with resource and funding opportunities. With regards to the Builder Fund, we’re looking to support hard-working innovators who are under-represented in their fields.”

Astek received funding from other programs within TEDCO as well. In addition to guidance and mentoring through the Maryland Innovation Initiative (MII), Astek received $165,000 in grants from the MII Technology Assessment Phase to de-risk the technology, followed by a $150,000 investment through MII’s Company Formation Phase in 2020. Astek also successfully participated in TEDCO’s SBIR/STTR Proposal Lab, which provides expert advice and proposal writing support to companies applying for federal funding, and was awarded a NSF SBIR grant for $256,000.

Astek recently completed the Y Combinator (YC). YC is a startup accelerator, based in San Francisco, working with companies to refine their pitch to investors. A highly competitive program, the YC has an approximate 3% acceptance rate. After a three month long program, the startups present their companies at the final Demo Day. Y Combinator has invested in over 3,000 companies including Airbnb, Dropbox, Stripe, Reddit, Instacart, Docker and Gusto. The combined valuation of YC companies is over $300B.

For entrepreneurs applying for their first investment from TEDCO’s Builder Fund, their company must be based in Maryland and led by an economically disadvantaged founder(s). For information on how to access TEDCO’s Builder Fund investment application, visit https://www.tedcomd.com/funding/builder-fund.

Source: TEDCO’s Pre-Seed Builder Fund Invests in Maryland Medical Device Start-up · BioBuzz